|
Alfaro R, Jaouad EKEB, Llorente S, Jimenez-Coll V, Martinez-Banaclocha H, Galian JA, Botella C, Moya-Quiles MR, Pena-Moral J, Minguela A, Legaz I, Muro M. Personalized Medicine for Kidney Transplantation: Association of Graft Survival and Acute Transplant Rejection with Genetic Variation in B Cell Activating Factor System Signaling. OMICS. 2021 Nov;25(11):725-737. doi: 10.1089/omi.2021.0099. Epub 2021 Oct 29. PubMed PMID: 34714153.
AÑO: 2021; IF: 3.978
|
34714153
|
Bernal E, Gimeno L, Alcaraz MJ, Quadeer AA, Moreno M, Martinez-Sanchez MV, Campillo JA, Gomez JM, Pelaez A, Garcia E, Herranz M, Hernandez-Olivo M, Martinez-Alfaro E, Alcaraz A, Munoz A, Cano A, McKay MR, Muro M, Minguela A. Activating Killer-Cell Immunoglobulin-Like Receptors Are Associated With the Severity of Coronavirus Disease 2019. J Infect Dis. 2021 Jul 15;224(2):229-240. doi: 10.1093/infdis/jiab228. PubMed PMID: 33928374; PubMed Central PMCID: PMC8135764.
AÑO: 2021; IF: 7.759
|
|
Legaz I, Bolarin JM, Campillo JA, Moya RM, Luna A, Osuna E, Minguela A, Sanchez-Bueno F, Alvarez MR, Muro M. Pretransplant ascites and encephalopathy and their influence on survival and liver graft rejection in alcoholic cirrhosis disease. Arch Med Sci. 2019 Jun 18;17(3):682-693. doi: 10.5114/aoms.2018.80651. eCollection 2021. PubMed PMID: 34025838; PubMed Central PMCID: PMC8130464.
AÑO: 2021; IF: 3.707
|
|
Alfaro R, Martinez-Banaclocha H, Llorente S, Jimenez-Coll V, Galian JA, Botella C, Moya-Quiles MR, Parrado A, Muro-Perez M, Minguela A, Legaz I, Muro M. Computational Prediction of Biomarkers, Pathways, and New Target Drugs in the Pathogenesis of Immune-Based Diseases Regarding Kidney Transplantation Rejection. Front Immunol. 2021 Dec 15;12:800968. doi: 10.3389/fimmu.2021.800968. eCollection 2021. PubMed PMID: 34975915; PubMed Central PMCID: PMC8714745.
AÑO: 2021; IF: 8.786
|
|
Vasco-Mogorron MA, Campillo JA, Periago A, Cabanas V, Berenguer M, Garcia-Garay MC, Gimeno L, Soto-Ramirez MF, Martinez-Hernandez MD, Muro M, Minguela A. Proliferation to Apoptosis Tumor Cell Ratio as a Biomarker to Improve Clinical Management of Pre-Malignant and Symptomatic Plasma Cell Neoplasms. Int J Mol Sci. 2021 Apr 9;22(8):3895. doi: 10.3390/ijms22083895. PubMed PMID: 33918790; PubMed Central PMCID: PMC8068942.
AÑO: 2021; IF: 6.208
|